Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study

MLA

Guoli Du, et al. “Acarbose-Metformin Is More Effective in Glycemic Variability Control than Repaglinide-Metformin in T2DM Patients Inadequately Controlled with Metformin: A Retrospective Cohort Study.” PeerJ, vol. 8, Oct. 2020, p. e9905. EBSCOhost, https://doi.org/10.7717/peerj.9905.

APA

Guoli Du, Wanrun Xie, Yinxia Su, Yao Ma, Xiaoming Gao, Sheng Jiang, & Huazheng Liang. (2020). Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study. PeerJ, 8, e9905. https://doi.org/10.7717/peerj.9905

Chicago

Guoli Du, Wanrun Xie, Yinxia Su, Yao Ma, Xiaoming Gao, Sheng Jiang, and Huazheng Liang. 2020. “Acarbose-Metformin Is More Effective in Glycemic Variability Control than Repaglinide-Metformin in T2DM Patients Inadequately Controlled with Metformin: A Retrospective Cohort Study.” PeerJ 8 (October): e9905. doi:10.7717/peerj.9905.